- Home
- ROIV vs CFR Comparison
ROIV vs CFR Comparison
Compare ROIV & CFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CFR
- Stock Information
- Founded
- ROIV 2014
- CFR 1868
- Country
- ROIV United Kingdom
- CFR United States
- Employees
- ROIV N/A
- CFR N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CFR Major Banks
- Sector
- ROIV Health Care
- CFR Finance
- Exchange
- ROIV Nasdaq
- CFR Nasdaq
- Market Cap
- ROIV 8.4B
- CFR 7.9B
- IPO Year
- ROIV N/A
- CFR N/A
- Fundamental
- Price
- ROIV $10.79
- CFR $131.23
- Analyst Decision
- ROIV Buy
- CFR Hold
- Analyst Count
- ROIV 4
- CFR 15
- Target Price
- ROIV $17.50
- CFR $133.13
- AVG Volume (30 Days)
- ROIV 5.9M
- CFR 367.4K
- Earning Date
- ROIV 05-29-2025
- CFR 05-01-2025
- Dividend Yield
- ROIV N/A
- CFR 3.05%
- EPS Growth
- ROIV N/A
- CFR 7.71
- EPS
- ROIV N/A
- CFR 9.11
- Revenue
- ROIV $122,585,000.00
- CFR $2,038,108,000.00
- Revenue This Year
- ROIV N/A
- CFR $11.62
- Revenue Next Year
- ROIV N/A
- CFR $3.90
- P/E Ratio
- ROIV N/A
- CFR $14.41
- Revenue Growth
- ROIV 140.04
- CFR 5.45
- 52 Week Low
- ROIV $8.73
- CFR $94.09
- 52 Week High
- ROIV $13.06
- CFR $147.64
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- CFR 68.66
- Support Level
- ROIV $10.58
- CFR $129.05
- Resistance Level
- ROIV $11.77
- CFR $131.82
- Average True Range (ATR)
- ROIV 0.34
- CFR 2.52
- MACD
- ROIV -0.07
- CFR 1.38
- Stochastic Oscillator
- ROIV 17.65
- CFR 96.63
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.